Startup Rise EU News’ Post

Nice & Green | Funding Solutions announced yesterday a new financing agreement with Oryzon Genomics, a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need. The funding of up to EUR 45M will enable Oryzon Genomics SA to extend its cash runway and continue their ongoing clinical trials in CNS and oncology. 🗣 Marc Cattelani, CEO of Nice & Green, commented: "We are pleased to embark on this journey with Oryzon to help strengthen their equity capital and support the advancement of their clinical trials. As a responsible and loyal financial partner, Nice & Green will remain attentive to the evolving financing needs of Oryzon's management team in the near and long term." 🗣 Dr. Carlos Buesa, CEO of Oryzon stated: "The current macroeconomic headwinds are a challenge for the stock markets, and the biotechnological sector has been particularly affected. In this unpredictable market situation, we are excited to have secured this financial support from Nice & Green. [...]" 👇 Learn more in our Press release: https://lnkd.in/eicNh_dX #funding #biopharma #partnership

#Phispers Week 6 - Weekly Pharma News Recap   Bonjour,   - Novo Nordisk’s parent buys Catalent Pharma Solutions for US$ 16.5 bn, Eli Lilly and Company calls for scrutiny  - Novartis buys MorphoSys for US$ 2.9 bn, gains promising bone-marrow cancer med - Amgen’s weight-loss drug shows impressive results in early-stage trial  - Johnson & Johnson Innovative Medicine’s closely watched autoimmune drug succeeds in mid, late-stage trials #Phispers in a minute - PharmaCompass.com's Weekly News Recap   #healthcare #pharmaceuticals #pharmanews #pharmaceuticalindustry #innovation #management #digitalmarketing #technology #startups #marketing #sales #strategy #networking #pharmacompass

#Phispers Week 6 - Weekly Pharma News Recap Bonjour, - Novo Nordisk’s parent buys Catalent Pharma Solutions for US$ 16.5 bn, Eli Lilly and Company calls for scrutiny - Novartis buys MorphoSys for US$ 2.9 bn, gains promising bone-marrow cancer med - Amgen’s weight-loss drug shows impressive results in early-stage trial - Johnson & Johnson Innovative Medicine’s closely watched autoimmune drug succeeds in mid, late-stage trials #Phispers this week - PharmaCompass.com's Weekly News Recap #healthcare #pharmaceuticals #pharmanews #pharmaceuticalindustry #innovation #management #digitalmarketing #technology #startups #marketing #sales #strategy #networking #pharmacompass https://lnkd.in/ddDksT4p

Apr. 22, 2024 Congrats to Rubedo Life Sciences. Personally and professionally very interested in this area: therapies for age-related diseases. "Rubedo Life Sciences, a biopharmaceutical company focused on developing therapies for age-related diseases, has closed a $40 million Series A financing round... led by Khosla Ventures and Ahren Innovation Capital." "Rubedo’s approach targets senescent cells which can accumulate over time and cause chronic inflammation, leading to fibrosis and tissue degeneration. The company’s drug discovery platform, Alembic, identifies pathologic cells like these to develop targeted therapeutics that can prevent or reverse the resulting age-related diseases."

Find out more about the biggest private biotech investments like never before in our revamped monthly feature! 💰 So, who exactly bagged the biggest healthcare investments in the first month of 2024? 💼 The answer to that question: Jixing Pharmaceuticals, Cour Pharmaceuticals Development Co., Inc., and OnCusp Therapeutics. 🚀 These three companies came out on top, each raising $100 million or more. 📊 But who else raised big, and how did companies perform by location?🌐 Check out our latest article! 👇️ https://loom.ly/pSRhqDk #biotechinvestments #healthcarefunding #investmentnews #healthcarestartups #biginvestments #globalhealth #biotechfinance #healthcareinnovation #investmenttrends #topbiotech

🔬 Exciting news in the #biotech sector! Industry veterans, including former Johnson & Johnson executives, have launched #ThirdArcBio, a promising new biotech company based in #Boston. This development highlights the growing focus on innovative treatments for complex diseases. Third Arc Bio is set to revolutionize the field with its work on multifunctional #antibodies targeting solid #tumors and #inflammatorydiseases. Backed by a substantial $165 million in series A financing, the company aims to bring multiple programs into clinical trials by early 2025. This significant investment underscores the confidence in their approach and the potential impact of their research. The establishment of Third Arc Bio represents a broader trend in the pharmaceutical industry towards targeted and multifunctional therapies. As the company progresses, it could set new standards in the treatment of cancer and inflammatory conditions, reflecting a shift towards more precise and effective healthcare solutions. Connect, Repost & Follow for more info on the pharmaceutical industry 🌍 #PharmaIndustry #Pharmaceutical #Biotech #ThirdArcBio #CancerResearch #Healthcare #cancer

📢€75m Raised by Merger for Innate Immunity Breakthrough 💰 Dutch biotech firm Forbion has led a €75m Series A financing round for newly formed company Calluna Pharma. Calluna was created through the merger of Oxitope Pharma and Arxx Therapeutics and aims to develop therapies for inflammatory and fibrotic diseases. Its pipeline includes four selective antibodies targeting immunological diseases, with CAL101 being the lead program. The funding will be used to develop Calluna's pipeline to key clinical milestones. #BioprocessUpdates #innateimmunity #merger #biotech #financing #SeriesA #pharmaceuticals #therapy #inflammatorydiseases #fibroticdiseases #antibodies #immunologicaldiseases #clinicalmilestones #Dutchbiotech #OxitopePharma #ArxxTherapeutics ▷ Read the full article here: 📎 https://lnkd.in/dJesXRF6

Stories making headlines today in the biopharma industry: Acorda Therapeutics, a renowned biotech company, has declared bankruptcy amidst legal and financial difficulties since 2017. The company has decided to sell off its assets, including a proprietary Multiple Sclerosis drug, to Merz Therapeutics for a sum of $185 million. In other sector news, Roivant has shared uplifting results from their Phase 2 eye disease drug trial, conducted in partnership with pharmaceutical giant Pfizer. Capitalizing on this success, Roivant is launching an unprecedented $1.5 billion share buyback program. However, contrasting fortunes struck Gritstone as its Phase 2 study for a novel cancer vaccine delivered mixed results, leading to a significant drop in its stock value. Despite the recent upset, Gritstone remains optimistic and is committed to moving forward with public stock offerings and advanced Phase 3 trials. Meanwhile, Praia Health, a healthcare startup pioneering in improving patient engagement with healthcare systems, managed to secure $20 million in a recent Series A funding round. The promising venture seeks to leverage this substantial capital influx to develop groundbreaking products that seamlessly connect consumers with vital healthcare services. In the corporate world, Zymeworks revealed the removal of CFO Christopher Astle, with CEO Kenneth Galbraith set to fill the position on a temporary basis. Concurrently, Gilead confirmed the expansion of its existing deal with Nurix. Lastly, Verve Therapeutics has decided to hit pause on its leading gene editing program following an adverse safety event. In its pursuit of safety and proficiency, the firm plans to shift gears towards a similar program that employs a different type of lipid delivery mechanism. #pharma #biotech #topstories #biodatastudio

Biopharma Funding Activity May 20th-24th ‘24 2 newly launched companies and more funding events… Get these weekly → https://lnkd.in/gDdkUYb3 – 𝐏𝐫𝐢𝐯𝐚𝐭𝐞 𝐅𝐮𝐧𝐝𝐢𝐧𝐠 – AltruBio Inc. 💸  Received an oversubscribed Series B financing of up to $225M led by BVF Partners LP, and other investors to support ongoing and planned Phase 2a and 2b clinical trials of immune checkpoint enhancer, ALTB-268, in ulcerative colitis. Pheon Therapeutics 💸  Completed a $120m Series B financing led by TCGX, with participation from BVF Partners and other investors. The funding will be used to further advance Pheon's differentiated ADC pipeline through clinical proof of concept for its first three assets in a wide range of solid tumors. SixPeaks Bio 💸  Launched with $110M funding: $30M in Series A led by Versant Ventures and $80M  non-dilutive financing from AstraZeneca. 𝐏𝐫𝐨𝐠𝐞𝐧𝐭𝐨𝐬 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 💸  Launched with $65M Series A financing led by Forbion to advance its multiple sclerosis program. Aktis Oncology 💸  Received $60M upfront cash payment for the collaboration in addition to an equity investment in Aktis by Lilly to generate novel tumor-targeting radiopharmaceuticals. – 𝐏𝐨𝐬𝐭-𝐈𝐏𝐎/𝐏𝐮𝐛𝐥𝐢𝐜 𝐅𝐮𝐧𝐝𝐢𝐧𝐠 – Bicycle Therapeutics 🏦  Announced $555M private investment in public equity. Cytokinetics 🏦  Announced pricing of $500M stock offering. Dyne Therapeutics 🏦  Announced pricing of $325.5M public offering. Erasca, Inc.  🏦  Announced closing of $184M offering. Foghorn Therapeutics Inc. 🏦  Announced pricing of $110M direct offering and pre-funded warrants. --- 👋 I'm Dominic Vacchiano, Co-founder of BiopharmIQ by Amp. We provide biopharma data to help with your sales/BD activities. 📰 Each week we share clinical/regulatory/funding news in an easy-to-digest format. #biotech #biopharma

📈 Big Moves in Biotech! Ono Pharmaceutical seals a transformative $2.4B deal, acquiring Deciphera Pharmaceuticals to revolutionize its cancer drug portfolio. 🎯 Ono bags an approved game-changer Qinlock, a potential blockbuster vimseltinib, and key commercial infrastructure to strengthen its US presence. Deciphera shareholders get a 70% premium windfall 💰 Despite global uncertainties, companies are moving ahead, innovating, and investing in treatments. This move signals strong confidence in the cancer therapy market's future.🧬 What are your thoughts on this strategic acquisition? #Biotech #CancerResearch #PharmaceuticalIndustry